Migraine - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 217 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Migraine - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Migraine - Pipeline Review, H2 2015', provides an overview of the Migraine's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Migraine
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Migraine
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Migraine Overview 10
Therapeutics Development 11
Pipeline Products for Migraine - Overview 11
Pipeline Products for Migraine - Comparative Analysis 12
Migraine - Therapeutics under Development by Companies 13
Migraine - Therapeutics under Investigation by Universities/Institutes 17
Migraine - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Migraine - Products under Development by Companies 22
Migraine - Products under Investigation by Universities/Institutes 27
Migraine - Companies Involved in Therapeutics Development 28
Ache Laboratorios Farmaceuticos S/A 28
Acorda Therapeutics, Inc. 29
Afferent Pharmaceuticals, Inc. 30
Alder Biopharmaceuticals Inc. 31
Allergan Plc 32
Amgen Inc. 33
Astellas Pharma Inc. 34
BioDelivery Sciences International, Inc. 35
Biofrontera AG 36
Charleston Laboratories, Inc. 37
CoLucid Pharmaceuticals, Inc. 38
Corium International, Inc. 39
D-Pharm Ltd. 40
Eli Lilly and Company 41
iCeutica, Inc. 42
Impel NeuroPharma, Inc. 43
Mallinckrodt Plc 44
Medestea Research & Production S.p.A. 45
Merck & Co., Inc. 46
Monosol Rx, LLC 47
NAL Pharmaceuticals Ltd. 48
Nektar Therapeutics 49
Noxxon Pharma AG 50
Otsuka Holdings Co., Ltd. 51
Pantarhei Bioscience BV 52
Pivot Pharmaceuticals Inc 53
Pozen, Inc. 54
Promius Pharma, LLC 55
RedHill Biopharma Ltd. 56
Revance Therapeutics, Inc. 57
Shin Nippon Biomedical Laboratories, Ltd. 58
Suda Ltd 59
Teva Pharmaceutical Industries Limited 60
TheraJect, Inc. 61
Trevena, Inc. 62
Trigemina, Inc. 63
Vertex Pharmaceuticals Incorporated 64
Zosano Pharma Corporation 65
Migraine - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Combination Products 67
Assessment by Target 68
Assessment by Mechanism of Action 72
Assessment by Route of Administration 75
Assessment by Molecule Type 77
Drug Profiles 79
(dextromethorphan hydrobromide + quinidine sulfate) - Drug Profile 79
(naproxen sodium + naratriptan hydrochloride) - Drug Profile 81
(sumatriptan succinate + naproxen sodium) - Drug Profile 82
(sumatriptan succinate + promethazine hydrochloride) - Drug Profile 84
AA-71 - Drug Profile 85
AF-130 - Drug Profile 86
AF-220 - Drug Profile 87
ALD-403 - Drug Profile 88
AMG-301 - Drug Profile 90
AMG-334 - Drug Profile 91
AST-003 - Drug Profile 92
BEMA Triptan - Drug Profile 93
BF-1 - Drug Profile 94
C-012 - Drug Profile 95
cloxyquin - Drug Profile 96
corticotropin - Drug Profile 97
daxibotulinumtoxin A - Drug Profile 99
Deina - Drug Profile 101
DFN-02 - Drug Profile 102
DFN-10 - Drug Profile 103
DFN-11 - Drug Profile 104
DFN-14 - Drug Profile 105
DFN-15 - Drug Profile 106
DFN-19 - Drug Profile 107
dihydroergotamine mesylate - Drug Profile 108
dihydroergotamine mesylate - Drug Profile 110
dihydroergotamine mesylate - Drug Profile 111
DORA-12 - Drug Profile 112
DP-VPA - Drug Profile 113
estetrol - Drug Profile 115
histamine dihydrochloride - Drug Profile 117
ICE-1209 - Drug Profile 118
ICE-1210 - Drug Profile 119
ICE-1211 - Drug Profile 120
ketoprofen - Drug Profile 121
lasmiditan succinate - Drug Profile 123
LY-2951742 - Drug Profile 125
MK-8031 - Drug Profile 127
NKTR-192 - Drug Profile 128
NOXL-41 - Drug Profile 129
NXN-188 - Drug Profile 130
NXN-462 - Drug Profile 131
oxytocin - Drug Profile 132
P-003 - Drug Profile 133
picotamide - Drug Profile 134
propofol hemisuccinate - Drug Profile 135
Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine - Drug Profile 136
rizatriptan benzoate - Drug Profile 137
rizatriptan benzoate - Drug Profile 139
rizatriptan benzoate - Drug Profile 140
Small Molecule to Antagonize CGRP for Migraine - Drug Profile 141
Small Molecule to Antagonize CGRP Receptor for Migraine - Drug Profile 142
Small Molecule to Antagonize Kappa Opioid Receptor for Migraine - Drug Profile 143
Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile 144
Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain - Drug Profile 145
Small Molecules to Agonize CB2 for Chronic Pain and Migraine - Drug Profile 146
Small Molecules to Antagonize 5-HT2B for Migraine - Drug Profile 147
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 148
Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile 149
Small Molecules to Inhibit CGRP Receptor for Migraine - Drug Profile 150
SST-8055 - Drug Profile 151
sumatriptan succinate - Drug Profile 152
sumatriptan succinate - Drug Profile 153
sumatriptan succinate - Drug Profile 155
sumatriptan succinate - Drug Profile 157
TEV-48125 - Drug Profile 158
Tribarcina - Drug Profile 160
TRV-250 - Drug Profile 161
ubrogepant - Drug Profile 163
zolmitriptan - Drug Profile 164
zolmitriptan - Drug Profile 165
zolmitriptan - Drug Profile 166
zolmitriptan - Drug Profile 167
Migraine - Recent Pipeline Updates 168
Migraine - Dormant Projects 195
Migraine - Discontinued Products 201
Migraine - Product Development Milestones 202
Featured News & Press Releases 202
Appendix 211
Methodology 211
Coverage 211
Secondary Research 211
Primary Research 211
Expert Panel Validation 211
Contact Us 211
Disclaimer 212

List of Tables

Number of Products under Development for Migraine, H2 2015 16
Number of Products under Development for Migraine - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 19
Number of Products under Development by Companies, H2 2015 (Contd..1) 20
Number of Products under Development by Companies, H2 2015 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H2 2015 22
Comparative Analysis by Late Stage Development, H2 2015 23
Comparative Analysis by Clinical Stage Development, H2 2015 24
Comparative Analysis by Early Stage Development, H2 2015 25
Comparative Analysis by Unknown Stage Development, H2 2015 26
Products under Development by Companies, H2 2015 27
Products under Development by Companies, H2 2015 (Contd..1) 28
Products under Development by Companies, H2 2015 (Contd..2) 29
Products under Development by Companies, H2 2015 (Contd..3) 30
Products under Development by Companies, H2 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H2 2015 32
Migraine - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 33
Migraine - Pipeline by Acorda Therapeutics, Inc., H2 2015 34
Migraine - Pipeline by Afferent Pharmaceuticals, Inc., H2 2015 35
Migraine - Pipeline by Alder Biopharmaceuticals Inc., H2 2015 36
Migraine - Pipeline by Allergan Plc, H2 2015 37
Migraine - Pipeline by Amgen Inc., H2 2015 38
Migraine - Pipeline by Astellas Pharma Inc., H2 2015 39
Migraine - Pipeline by BioDelivery Sciences International, Inc., H2 2015 40
Migraine - Pipeline by Biofrontera AG, H2 2015 41
Migraine - Pipeline by Charleston Laboratories, Inc., H2 2015 42
Migraine - Pipeline by CoLucid Pharmaceuticals, Inc., H2 2015 43
Migraine - Pipeline by Corium International, Inc., H2 2015 44
Migraine - Pipeline by D-Pharm Ltd., H2 2015 45
Migraine - Pipeline by Eli Lilly and Company, H2 2015 46
Migraine - Pipeline by iCeutica, Inc., H2 2015 47
Migraine - Pipeline by Impel NeuroPharma, Inc., H2 2015 48
Migraine - Pipeline by Mallinckrodt Plc, H2 2015 49
Migraine - Pipeline by Medestea Research & Production S.p.A., H2 2015 50
Migraine - Pipeline by Merck & Co., Inc., H2 2015 51
Migraine - Pipeline by Monosol Rx, LLC, H2 2015 52
Migraine - Pipeline by NAL Pharmaceuticals Ltd., H2 2015 53
Migraine - Pipeline by Nektar Therapeutics, H2 2015 54
Migraine - Pipeline by Noxxon Pharma AG, H2 2015 55
Migraine - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 56
Migraine - Pipeline by Pantarhei Bioscience BV, H2 2015 57
Migraine - Pipeline by Pivot Pharmaceuticals Inc, H2 2015 58
Migraine - Pipeline by Pozen, Inc., H2 2015 59
Migraine - Pipeline by Promius Pharma, LLC, H2 2015 60
Migraine - Pipeline by RedHill Biopharma Ltd., H2 2015 61
Migraine - Pipeline by Revance Therapeutics, Inc., H2 2015 62
Migraine - Pipeline by Shin Nippon Biomedical Laboratories, Ltd., H2 2015 63
Migraine - Pipeline by Suda Ltd, H2 2015 64
Migraine - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 65
Migraine - Pipeline by TheraJect, Inc., H2 2015 66
Migraine - Pipeline by Trevena, Inc., H2 2015 67
Migraine - Pipeline by Trigemina, Inc., H2 2015 68
Migraine - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2015 69
Migraine - Pipeline by Zosano Pharma Corporation, H2 2015 70
Assessment by Monotherapy Products, H2 2015 71
Assessment by Combination Products, H2 2015 72
Number of Products by Stage and Target, H2 2015 74
Number of Products by Stage and Mechanism of Action, H2 2015 78
Number of Products by Stage and Route of Administration, H2 2015 81
Number of Products by Stage and Molecule Type, H2 2015 83
Migraine Therapeutics - Recent Pipeline Updates, H2 2015 173
Migraine - Dormant Projects, H2 2015 200
Migraine - Dormant Projects (Contd..1), H2 2015 201
Migraine - Dormant Projects (Contd..2), H2 2015 202
Migraine - Dormant Projects (Contd..3), H2 2015 203
Migraine - Dormant Projects (Contd..4), H2 2015 204
Migraine - Dormant Projects (Contd..5), H2 2015 205
Migraine - Discontinued Products, H2 2015 206